Scaffold rearrangement of dihydroxypyrimidine inhibitors of HIV integrase: Docking model revisited.

[1]  A. Engelman,et al.  Retroviral intasome assembly and inhibition of DNA strand transfer , 2010, Nature.

[2]  J. Alcamí,et al.  Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs , 2009, Nature Reviews Microbiology.

[3]  Z. Debyser,et al.  Pharmacophore‐Based Discovery of Small‐Molecule Inhibitors of Protein–Protein Interactions between HIV‐1 Integrase and Cellular Cofactor LEDGF/p75 , 2009, ChemMedChem.

[4]  Yves Pommier,et al.  HIV-1 IN inhibitors: 2010 update and perspectives. , 2009, Current topics in medicinal chemistry.

[5]  R. Stroud,et al.  Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs , 2009, Proceedings of the National Academy of Sciences.

[6]  E. Garvey,et al.  Synthesis and antiviral activity of 7-benzyl-4-hydroxy-1,5-naphthyridin-2(1H)-one HIV integrase inhibitors. , 2009, Journal of medicinal chemistry.

[7]  Z. Debyser,et al.  Docking studies on a new human immunodeficiency virus integrase-Mg-DNA complex: phenyl ring exploration and synthesis of 1H-benzylindole derivatives through fluorine substitutions. , 2009, Journal of medicinal chemistry.

[8]  B. Dong,et al.  Raltegravir: the first HIV integrase inhibitor. , 2008, Clinical therapeutics.

[9]  E. Kodama,et al.  Elvitegravir: an emerging HIV integrase inhibitor , 2008 .

[10]  D. Hazuda,et al.  Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. , 2008, Journal of medicinal chemistry.

[11]  S. Swaminathan,et al.  Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors. , 2008, Journal of molecular biology.

[12]  Myriam Witvrouw,et al.  A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series. , 2008, Bioorganic & medicinal chemistry letters.

[13]  Myriam Witvrouw,et al.  Quinolone 3-carboxylic acid pharmacophore: design of second generation HIV-1 integrase inhibitors. , 2008, Journal of medicinal chemistry.

[14]  E. Garvey,et al.  The Naphthyridinone GSK364735 Is a Novel, Potent Human Immunodeficiency Virus Type 1 Integrase Inhibitor and Antiretroviral , 2007, Antimicrobial Agents and Chemotherapy.

[15]  D. Hazuda,et al.  Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors. , 2007, Journal of medicinal chemistry.

[16]  Satoru Ikeda,et al.  Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. , 2006, Journal of medicinal chemistry.

[17]  J. Briggs,et al.  Dynamic pharmacophore model optimization: identification of novel HIV-1 integrase inhibitors. , 2006, Journal of medicinal chemistry.

[18]  R. Dayam,et al.  Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase. , 2005, Journal of medicinal chemistry.

[19]  R. Craigie,et al.  Seeing is believing: structure of the catalytic domain of HIV-1 integrase in complex with human LEDGF/p75. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Myriam Witvrouw,et al.  Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors. , 2005, Journal of medicinal chemistry.

[21]  Y. Pommier,et al.  Integrase inhibitors to treat HIV/Aids , 2005, Nature Reviews Drug Discovery.

[22]  J. Briggs,et al.  Dynamic receptor-based pharmacophore model development and its application in designing novel HIV-1 integrase inhibitors. , 2005, Journal of medicinal chemistry.

[23]  R. Shoemaker,et al.  β-Diketo Acid Pharmacophore Hypothesis. 1. Discovery of a Novel Class of HIV-1 Integrase Inhibitors , 2005 .

[24]  Mark Embrey,et al.  A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Alessandro Brigo,et al.  HIV-1 integrase pharmacophore model derived from diverse classes of inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[26]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[27]  R M Stroud,et al.  Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[28]  F. Bushman,et al.  Developing a dynamic pharmacophore model for HIV-1 integrase. , 2000, Journal of medicinal chemistry.

[29]  J A Grobler,et al.  Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. , 2000, Science.

[30]  G. Cohen,et al.  Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Davies,et al.  Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[32]  E. Asante-Appiah,et al.  Molecular mechanisms in retrovirus DNA integration. , 1997, Antiviral research.

[33]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[34]  A. Engelman,et al.  Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. , 1994, Science.

[35]  A. Engelman,et al.  Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro , 1992, Journal of virology.

[36]  W. C. Still,et al.  Semianalytical treatment of solvation for molecular mechanics and dynamics , 1990 .

[37]  Sarah Palmer,et al.  HIV reservoirs, latency, and reactivation: prospects for eradication. , 2010, Antiviral research.

[38]  Xiaowu Chen,et al.  Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. , 2010, Antiviral research.

[39]  Z. Debyser,et al.  HIV-1 integration: an interplay between HIV-1 integrase, cellular and viral proteins. , 2005, AIDS reviews.